ClinicalTrials.gg
CompletedNCT03518047IMMPRESSUpdated Jan 25, 2021

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation

A Phase 3 interventional study of risankizumab and placebo for rizankizumab in Psoriasis, sponsored by AbbVie. Completed at 6 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
24th of 30
50 · median 162
Started
2018
with 2 others
Phase 3
17 of 30
none open now
Registered
15th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 24th largest by enrollment, is one of 3 that started in 2018, is one of 17 in phase 3, and was the 15th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug.
  • Moderate to severe chronic plaque psoriasis at both Screening and Baseline (Randomization) Visits
  • Candidates for systemic therapy or phototherapy for psoriasis treatment as assessed by the investigator

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with an anti-interleukin (IL)-17 or anti-IL12/23p40 or anti-IL-23p19 inhibitor
  • Concurrent therapy with a biologic and/or other systemic therapy
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for risankizumab by subcutaneous (SC) injection.

    Drug: placebo for rizankizumab

  • Experimental
    Risankizumab

    Risankizumab by subcutaneous (SC) injection.

    Drug: risankizumab

Interventions

  • rizankizumab subcutaneous (SC) infusion

    Also known as: ABBV-066, BI 655066

  • Drugplacebo for rizankizumab

    placebo for rizankizumab subcutaneous (SC) infusion

06

What researchers measure

Primary outcomes

  1. Proportion of participants with a 90% reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16

    The PASI score is an established measure of clinical efficacy for psoriasis medications.

    Time frame: Week 16

Secondary outcomes

  1. Proportion of participants with Static Physician Global Assessment (sPGA) score of clear or almost clear (0, 1) at Week 16

    The sPGA is based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions.

    Time frame: Week 16

  2. Proportion of participants with a 75% reduction from Baseline Psoriasis Area and Severity Index (PASI 75) at Week 16

    The PASI score is an established measure of clinical efficacy for psoriasis medications.

    Time frame: Week 16

  3. Proportion of participants with a 100% reduction from Baseline Psoriasis Area and Severity Index (PASI 100) at Week 16

    The PASI score is an established measure of clinical efficacy for psoriasis medications.

    Time frame: Week 16

  4. Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16

    The DLQI is a self-administered, ten-question questionnaire used to assess the effect of different skin diseases on a subject's quality of life, overall health, and disability status. Scores range from 0 (not relevant/not at all) to 3 (very much).

    Time frame: Week 16

07

Study locations

6 sites
  • GBUZ Clinical Dermatovenerology Dispensary of MoH of Krasnodar region /ID# 201713
    Krasnodar, Krasnodarskiy Kray 350020, Russian Federation
  • Family Outpatient clinic#4 LLC /ID# 207441
    Korolev, Moskva 141060, Russian Federation
  • SBHI KVD # 10 Clinic of Dermatology and venerology /ID# 200615
    Saint-Petersburg, Sankt-Peterburg 194021, Russian Federation
  • LLC ArsVitae Severo-Zapad /ID# 200658
    Saint-Petersburg, Sankt-Peterburg 194223, Russian Federation
  • LLC Kurator /ID# 200616
    Saint-Petersburg, Sankt-Peterburg 196240, Russian Federation
  • Alliance Biomedical Ural Group /ID# 201681
    Izhevsk, Udmurtskaya Respublika 426061, Russian Federation
08

References and documents

Publications

  • Odnopozova L, Edin A, Sukharev A, Wu T, Aydin K, Kelly M, Khotko A. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation. Dermatol Ther (Heidelb). 2022 Sep;12(9):2063-2075. doi: 10.1007/s13555-022-00776-0. Epub 2022 Aug 2. PubMed 35917057 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Feb 2020, 18 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2018
First posted
May 8, 2018
StartActual
Jul 19, 2018
Primary completionActual
Feb 11, 2020
CompletionActual
Feb 11, 2020
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03518047
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 8, 2018
Start date
Jul 19, 2018
Primary completion
Feb 11, 2020
Completion
Feb 11, 2020
Last update
Jan 25, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion